Sinonasal inverted papilloma, known for its non-cancerous yet aggressive nature, poses significant challenges to healthcare. With high recurrence potential, the tumor necessitates surgical intervention, primarily through endoscopic sinus surgery (ESS) or external approaches based on its characteristics. Although both techniques offer clinical benefits, a thorough examination of their economic impact remains lacking. Recent research highlights an important comparison not only in outcomes but also in cost-effectiveness, aiming to shed light on long-term healthcare savings and patient benefits.
Study Methodology
A comprehensive retrospective analysis examined the economic efficiency of ESS versus external surgery in treating inverted papilloma. The study involved 50 participants treated between 1995 and 2018, split between these two surgical techniques. Hospital records provided data on direct medical costs, while the effectiveness was gauged using a 5-year disease-free survival (DFS) metric. Both cost-minimization and cost-effectiveness assessments, including analysis conducted by the Krouse staging system, were integral to the study.
Key Findings
Results demonstrated that the median expense for patients undergoing ESS was remarkably lower at €7567.23, compared to €11,456.40 for those treated with the external approach. This highlights a cost-saving of approximately €4000 per patient through ESS. While external surgery offered a marginally better DFS rate, its elevated incremental cost-effectiveness ratio (ICER) of €40,837.13 questioned the value-for-money aspect of the slight DFS advantage. For patients with localized tumors (Krouse I-II), ESS provided an economically superior alternative without compromising on effectiveness.
Key inferences from the study include:
– Substantial cost reduction per patient is seen with endoscopic surgery.
– The financial burden of external surgery is not justified by its marginal increase in DFS.
– Choosing surgical methods should consider both economic and clinical factors, particularly for early-stage tumors.
Ultimately, endoscopic surgery offers a compelling cost-effectiveness profile, ensuring maximum treatment benefit without undue financial strain. Although external techniques achieve slightly higher DFS, they demand significant investment, which may not be justifiable given the close efficacy of ESS. Careful consideration of economic impacts in treatment planning thus emerges as crucial, especially for healthcare systems aiming to balance cost constraints with optimal patient outcomes. Understanding the marriage of cost and care in surgical decision-making enhances strategic healthcare planning and reinforces efficient resource allocation.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
